Drug intelligence / Profile preview

BT-001

Development stage: Preclinical
Lead developer: Biora Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral

Overview

**BT-001**, formerly **PGN-001**, is an investigational oral drug-device combination developed by Progenity and subsequently Biora Therapeutics for ulcerative colitis. It contains a liquid formulation or variant of the anti-tumor necrosis factor alpha monoclonal antibody adalimumab and is delivered by Biora's ingestible NaviCap targeted-delivery capsule to the lower gastrointestinal tract. Local colonic delivery is intended to neutralize tumor necrosis factor alpha at inflamed intestinal tissue while limiting systemic exposure relative to conventional injected adalimumab. ([bioratherapeutics.com](https://www.bioratherapeutics.com/pipeline/navicap-targeted-therapeutic-delivery-platform))

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on BT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT-001.

Explore the full profile